Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Resistance Training Reduces Risk of Sarcopenia in Patients With Cirrhosis.

Tandon P, Dunn MA, Duarte-Rojo A.

Clin Gastroenterol Hepatol. 2019 Oct 4. pii: S1542-3565(19)31079-1. doi: 10.1016/j.cgh.2019.09.030. [Epub ahead of print] No abstract available.

PMID:
31589977
2.

Association Between Liver Transplant Wait-list Mortality and Frailty Based on Body Mass Index.

Haugen CE, McAdams-DeMarco M, Verna EC, Rahimi R, Kappus MR, Dunn MA, Volk ML, Gurakar A, Duarte-Rojo A, Ganger DR, O'Leary JG, Ladner D, Garonzik-Wang J, Segev DL, Lai JC.

JAMA Surg. 2019 Sep 11. doi: 10.1001/jamasurg.2019.2845. [Epub ahead of print]

PMID:
31509169
3.

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC.

Gastroenterology. 2019 Jul 30. pii: S0016-5085(19)41137-2. doi: 10.1053/j.gastro.2019.07.040. [Epub ahead of print]

PMID:
31374215
4.

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.

Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG.

Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]

PMID:
31357028
5.

A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Carey EJ, Lai JC, Sonnenday C, Tapper EB, Tandon P, Duarte-Rojo A, Dunn MA, Tsien C, Kallwitz ER, Ng V, Dasarathy S, Kappus M, Bashir MR, Montano-Loza AJ.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828. [Epub ahead of print]

PMID:
31220351
6.

Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice.

Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, Carey EJ, Dasarathy S, Kamath BM, Kappus MR, Montano-Loza AJ, Nagai S, Tandon P.

Am J Transplant. 2019 Jul;19(7):1896-1906. doi: 10.1111/ajt.15392. Epub 2019 May 8.

PMID:
30980701
7.

Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies.

Flud CR, Duarte-Rojo A.

J Clin Exp Hepatol. 2019 Jan-Feb;9(1):112-116. doi: 10.1016/j.jceh.2018.04.009. Epub 2018 May 4. Review.

PMID:
30765944
8.

Frailty Associated With Waitlist Mortality Independent of Ascites and Hepatic Encephalopathy in a Multicenter Study.

Lai JC, Rahimi RS, Verna EC, Kappus MR, Dunn MA, McAdams-DeMarco M, Haugen CE, Volk ML, Duarte-Rojo A, Ganger DR, O'Leary JG, Dodge JL, Ladner D, Segev DL.

Gastroenterology. 2019 May;156(6):1675-1682. doi: 10.1053/j.gastro.2019.01.028. Epub 2019 Jan 19.

PMID:
30668935
9.

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.

Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.

PMID:
30660729
10.

Report from the American Society of Transplantation on frailty in solid organ transplantation.

Kobashigawa J, Dadhania D, Bhorade S, Adey D, Berger J, Bhat G, Budev M, Duarte-Rojo A, Dunn M, Hall S, Harhay MN, Johansen KL, Joseph S, Kennedy CC, Kransdorf E, Lentine KL, Lynch RJ, McAdams-DeMarco M, Nagai S, Olymbios M, Patel J, Pinney S, Schaenman J, Segev DL, Shah P, Singer LG, Singer JP, Sonnenday C, Tandon P, Tapper E, Tullius SG, Wilson M, Zamora M, Lai JC.

Am J Transplant. 2019 Apr;19(4):984-994. doi: 10.1111/ajt.15198. Epub 2018 Dec 22.

PMID:
30506632
11.

Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing.

Duarte-Rojo A, Allampati S, Thacker LR, Flud CR, Patidar KR, White MB, Klair JS, Heuman DM, Wade JB, Gavis EA, Bajaj JS.

Metab Brain Dis. 2019 Feb;34(1):289-295. doi: 10.1007/s11011-018-0350-z. Epub 2018 Nov 30.

PMID:
30506333
12.

The association between obesity and outcomes in acute pancreatitis: an individual patient data meta-analysis.

Smeets XJNM, Knoester I, Grooteman KV, Singh VK, Banks PA, Papachristou GI, Duarte-Rojo A, Robles-Diaz G, Kievit W, Besselink MGH, Verdonk RC, Van Santvoort HC, Drenth JPH, Belias M, Van Geenen EJM; Dutch Pancreatitis Study Group.

Eur J Gastroenterol Hepatol. 2019 Mar;31(3):316-322. doi: 10.1097/MEG.0000000000001300.

PMID:
30399003
13.

HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.

van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky JM, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer H, Feld JJ.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.

PMID:
30274834
14.

Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis.

Addepally NS, George N, Martinez-Macias R, Garcia-Saenz-de-Sicilia M, Kim WR, Duarte-Rojo A.

Dig Dis Sci. 2018 Dec;63(12):3498-3508. doi: 10.1007/s10620-018-5265-3. Epub 2018 Aug 29.

PMID:
30159733
15.

Exercise in cirrhosis: Translating evidence and experience to practice.

Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, Holman J, Howes N, Haykowsky MJF, Josbeno DA, McNeely M.

J Hepatol. 2018 Nov;69(5):1164-1177. doi: 10.1016/j.jhep.2018.06.017. Epub 2018 Jun 30. Review.

PMID:
29964066
16.

Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, Montano-Loza AJ.

Hepatol Int. 2018 Jul;12(4):377-386. doi: 10.1007/s12072-018-9875-9. Epub 2018 Jun 7.

PMID:
29881992
17.

Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy.

George N, Harrell SM, Rhodes KD, Duarte-Rojo A.

Ann Hepatol. 2018 January-February;17(1):76-84. doi: 10.5604/01.3001.0010.7537.

18.

Hepatic Steatosis and its Effects on Fibrosis in Patients With Chronic Hepatitis B Virus Infection.

Garcia-Saenz-de-Sicilia M, Duarte-Rojo A.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):491-494. doi: 10.1016/j.cgh.2017.12.018. Epub 2017 Dec 15. No abstract available.

PMID:
29248735
19.

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.

Thompson J, Jones N, Al-Khafaji A, Malik S, Reich D, Munoz S, MacNicholas R, Hassanein T, Teperman L, Stein L, Duarte-Rojo A, Malik R, Adhami T, Asrani S, Shah N, Gaglio P, Duddempudi A, Borg B, Jalan R, Brown R, Patton H, Satoskar R, Rossi S, Parikh A, ElSharkawy A, Mantry P, Sher L, Wolf D, Hart M, Landis C, Wigg A, Habib S, McCaughan G, Colquhoun S, Henry A, Bedard P, Landeen L, Millis M, Ashley R, Frank W, Henry A, Stange J, Subramanian R; VTI-208 Study Group.

Liver Transpl. 2018 Mar;24(3):380-393. doi: 10.1002/lt.24986.

20.

Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list.

Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, Macías-Rodríguez RU, Ferrando A, Kim WR.

Liver Transpl. 2018 Jan;24(1):122-139. doi: 10.1002/lt.24958.

21.

Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.

Maan R, Feld JJ, Duarte-Rojo A.

Aliment Pharmacol Ther. 2017 Aug;46(3):379-380. doi: 10.1111/apt.14187. No abstract available.

22.

The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.

Maan R, Al Marzooqi SH, Klair JS, Karkada J, Cerocchi O, Kowgier M, Harrell SM, Rhodes KD, Janssen HLA, Feld JJ, Duarte-Rojo A.

Aliment Pharmacol Ther. 2017 Jul;46(1):46-55. doi: 10.1111/apt.14117. Epub 2017 May 3.

23.

Corrigendum: A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.

Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, Chavez-Araujo R, Prado V, de Lourdes Candolo-Martinelli A, Holanda-Almeida P, Becerra-Martins-de-Oliveira B, Fernandez-de-Almeida S, Bataller R, Caballeria J, Duarte-Rojo A.

Am J Gastroenterol. 2017 Apr;112(4):666. doi: 10.1038/ajg.2017.76. No abstract available.

PMID:
28381859
24.

Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis.

Ruiz-Margáin A, Macías-Rodríguez RU, Ampuero J, Cubero FJ, Chi-Cervera L, Ríos-Torres SL, Duarte-Rojo A, Espinosa-Cuevas Á, Romero-Gómez M, Torre A.

World J Gastroenterol. 2016 Dec 7;22(45):10064-10070. doi: 10.3748/wjg.v22.i45.10064.

25.

A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis.

Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, Chavez-Araujo R, Prado V, de Lourdes Candolo-Martinelli A, Holanda-Almeida P, Becerra-Martins-de-Oliveira B, Fernandez-de-Almeida S, Bataller R, Caballeria J, Duarte-Rojo A.

Am J Gastroenterol. 2017 Feb;112(2):306-315. doi: 10.1038/ajg.2016.539. Epub 2016 Dec 6. Erratum in: Am J Gastroenterol. 2017 Apr;112(4):666.

PMID:
27922027
26.

Changes in Hepatic Venous Pressure Gradient Induced by Physical Exercise in Cirrhosis: Results of a Pilot Randomized Open Clinical Trial.

Macías-Rodríguez RU, Ilarraza-Lomelí H, Ruiz-Margáin A, Ponce-de-León-Rosales S, Vargas-Vorácková F, García-Flores O, Torre A, Duarte-Rojo A.

Clin Transl Gastroenterol. 2016 Jul 14;7(7):e180. doi: 10.1038/ctg.2016.38.

27.

Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.

Gonzalez HC, Duarte-Rojo A.

Curr Gastroenterol Rep. 2016 Jul;18(7):32. doi: 10.1007/s11894-016-0508-y. Review.

PMID:
27177638
28.

Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy.

Duarte-Rojo A, Ruiz-Margáin A, Macias-Rodriguez RU, Cubero FJ, Estradas-Trujillo J, Muñoz-Fuentes RM, Torre A.

World J Gastroenterol. 2016 May 7;22(17):4397-402. doi: 10.3748/wjg.v22.i17.4397.

29.

Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015.

Wiegand J, van Bömmel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T.

J Hepatol. 2016 Jun;64(6):1428-45. doi: 10.1016/j.jhep.2016.02.020. Epub 2016 Feb 21. Review. No abstract available.

PMID:
26902945
30.

Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.

Duarte-Rojo A, Fischer SE, Adeyi O, Zita D, Deneke MG, Selzner N, Chen L, Malespin M, Cotler SJ, McGilvray ID, Feld JJ.

J Viral Hepat. 2016 May;23(5):340-7. doi: 10.1111/jvh.12494. Epub 2015 Dec 29.

PMID:
26710754
31.

Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.

van der Meer AJ, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

J Gastroenterol Hepatol. 2016 Jun;31(6):1168-76. doi: 10.1111/jgh.13252.

32.

Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study.

Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, John B, Heuman DM, Wade JB, Flud C, O'Shea R, Gavis EA, Unser AB, Bajaj JS.

Am J Gastroenterol. 2016 Jan;111(1):78-86. doi: 10.1038/ajg.2015.377. Epub 2015 Dec 8.

PMID:
26644276
33.

Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis.

Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, Baracos VE, Sawyer MB, Pang JX, Beaumont C, Esfandiari N, Myers RP.

Clin Transl Gastroenterol. 2015 Jul 16;6:e102. doi: 10.1038/ctg.2015.31.

34.

Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study.

Ruiz-Margáin A, Macías-Rodríguez RU, Duarte-Rojo A, Ríos-Torres SL, Espinosa-Cuevas Á, Torre A.

Dig Liver Dis. 2015 Apr;47(4):309-14. doi: 10.1016/j.dld.2014.12.015. Epub 2015 Jan 3.

PMID:
25618555
35.

Seizures as a Potential Complication of Treatment With Simeprevir and Sofosbuvir.

Syal G, Heldenbrand SD, Duarte-Rojo A.

Am J Ther. 2016 Mar-Apr;23(2):e570-1. doi: 10.1097/MJT.0000000000000188.

PMID:
25549078
36.

MELD exception for liver transplantation in portopulmonary hypertension: current implementation and future considerations.

Porres-Aguilar M, Bartolome SD, Duarte-Rojo A.

Ann Hepatol. 2014 Nov-Dec;13(6):719-21. No abstract available.

37.

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.

Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-Rojo A.

Ann Hepatol. 2014 Jul-Aug;13(4):461-5.

38.

Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters.

van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL.

Gut. 2015 Feb;64(2):322-31. doi: 10.1136/gutjnl-2013-305357. Epub 2014 May 9.

PMID:
24815676
39.

Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy.

Macías-Rodríguez RU, Duarte-Rojo A, Cantú-Brito C, Sauerbruch T, Ruiz-Margáin A, Trebicka J, Green-Gómez M, Díaz Ramírez JB, Sierra Beltrán M, Uribe-Esquivel M, Torre A.

Liver Int. 2015 Feb;35(2):344-52. doi: 10.1111/liv.12557. Epub 2014 Apr 29.

PMID:
24690075
40.

[Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy].

Deneke MG, Dranoff JA, Duarte-Rojo A.

Rev Gastroenterol Mex. 2014 Jan-Mar;79(1):64-6. doi: 10.1016/j.rgmx.2013.09.003. Epub 2014 Mar 26. Spanish. No abstract available.

41.

A histologic scoring system for prognosis of patients with alcoholic hepatitis.

Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, Augustin S, Mookerjee RP, Michelena J, Smyrk TC, Buob D, Leteurtre E, Rincón D, Ruiz P, García-Pagán JC, Guerrero-Marquez C, Jones PD, Barritt AS 4th, Arroyo V, Bruguera M, Bañares R, Ginès P, Caballería J, Roskams T, Nevens F, Jalan R, Mathurin P, Shah VH, Bataller R.

Gastroenterology. 2014 May;146(5):1231-9.e1-6. doi: 10.1053/j.gastro.2014.01.018. Epub 2014 Jan 15.

42.
43.

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

J Viral Hepat. 2014 Aug;21(8):568-77. doi: 10.1111/jvh.12185. Epub 2013 Oct 10.

PMID:
24118177
44.

Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.

Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Poterucha JJ, Charlton MR.

Liver Transpl. 2013 Dec;19(12):1311-7. doi: 10.1002/lt.23733. Review.

45.

The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients.

Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Duarte-Rojo A, Elkashab M, Myers RP.

Hepatol Int. 2013 Jun;7(2):592-9. doi: 10.1007/s12072-012-9401-4. Epub 2012 Sep 29.

PMID:
26201792
46.

Transthoracic echocardiography screening for the detection of portopulmonary hypertension: a work in progress.

Porres-Aguilar M, Duarte-Rojo A, Krowka MJ.

Liver Transpl. 2013 Jun;19(6):573-4. doi: 10.1002/lt.23663. No abstract available.

47.

A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C.

Pattullo V, Duarte-Rojo A, Soliman W, Vargas-Vorackova F, Sockalingam S, Fantus IG, Allard J, Heathcote J.

Liver Int. 2013 Mar;33(3):410-9. doi: 10.1111/liv.12041. Epub 2012 Dec 26.

PMID:
23278982
48.

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients.

Durango E, Dietrich C, Seitz HK, Kunz CU, Pomier-Layrargues GT, Duarte-Rojo A, Beaton M, Elkhashab M, Myers RP, Mueller S.

Hepat Med. 2013 Jul 4;5:43-52. doi: 10.2147/HMER.S45234. eCollection 2013.

49.

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL.

JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.

PMID:
23268517
50.

Interleukin-28B polymorphism in hepatitis C and liver transplantation.

Duarte-Rojo A, Deneke MG, Charlton MR.

Liver Transpl. 2013 Jan;19(1):49-58. doi: 10.1002/lt.23554.

Supplemental Content

Loading ...
Support Center